Common critical pathways in embryogenesis and cancer

Acta Oncologica

Volumn 45, Issue 4, 2006, Pages 375-388

  Kelleher, Fergal ^a   Fennelly, David ^a   Rafferty, Mairin ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BETA CATENIN; COMPLEMENTARY DNA; CYCLIN D1; JAGGED1; MESSENGER RNA; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; OSTEOGENIC PROTEIN 1; PROCOLLAGEN C PROTEINASE; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR HES 1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN; VITRONECTIN RECEPTOR; WNT PROTEIN;

ADENOSQUAMOUS CARCINOMA; AUTOSOMAL DOMINANT DISORDER; BASAL CELL NEVUS SYNDROME; BREAST CANCER; CELL FATE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CHROMOSOME LOSS; COLON POLYPOSIS; CORRELATION ANALYSIS; CYTOLOGY; DENYS DRASH SYNDROME; DESMOID TUMOR; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; DNA MICROARRAY; EMBRYO DEVELOPMENT; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; MESENCHYME CELL; MORPHOGENESIS; NEPHROBLASTOMA; NEUROBLASTOMA; NONSENSE MUTATION; ONCOGENE C MYB; PATHOLOGY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALIVARY GLAND CANCER; SKIN CANCER; STOMACH CARCINOMA; T CELL LEUKEMIA; T CELL LYMPHOMA; UTERINE CERVIX CANCER;

ANIMALS; EMBRYONIC DEVELOPMENT; EPITHELIAL CELLS; HUMANS; MESODERM; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33745065756     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600602946     Document Type: Review

References (112)

1. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995;154(1):8-20.
2. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2(2):84-9.
3. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161(5):1881-91.
4. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344(25):1904-9.
5. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115(1):85-98.
6. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117(7):927-39.
7. Kang Y, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004;118(3):277-9.
8. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002;21(20):3241-6.
9. Mora J, Gerald WL, Qin J, Cheung NK. Molecular genetics of neuroblastoma and the implications for clinical management: A review of the MSKCC experience. Oncologist 2001;6(3):263-8.
10. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001;19(12):3080-90.
11. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004;6(6):625-30.
12. Rettig WJ, Spengler BA, Chesa PG, Old LJ, Biedler JL. Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res 1987;47(5):1383-9.
13. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 2005;433(7023):317-22.
14. Sarkar L, Sharpe PT. Expression of Wnt signalling pathway genes during tooth development. Mech Dev 1999;85(1-2):197-200.
15. Shimogori T, Banuchi V, Ng HY, Strauss JB, Grove EA. Embryonic signaling centers expressing BMP, WNT and FGF proteins interact to pattern the cerebral cortex. Development 2004;131(22):5639-47.
16. Yang Y. Wnts and wing: Wnt signaling in vertebrate limb development and musculoskeletal morphogenesis. Birth Defects Res C Embryo Today 2003;69(4):305-17.
17. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398(6726):422-6.
18. Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004;74(5):1043-50.
19. Clapper ML, Coudry J, Chang WC. beta-catenin-mediated signaling: A molecular target for early chemopreventive intervention. Mutat Res 2004;555(1-2):97-105.
20. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, et al. Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000;97(8):4262-6.
21. Roberts LR, Gores GJ. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25(2):212-25.
22. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y, et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 2004;14(12):1020-9.
23. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: Down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenorypes and poor prognosis. Am J Pathol 2001;158(3):987-96.
24. Heathcott RW, Morison IM, Gubler MC, Corbett R, Reeve AE. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X. Hum Mutat 2002;19(4):462.
25. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31(1):99-109.
26. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999;59(17):4257-60.
27. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18(47):6615-20.
28. Moreno-Bueno G, Gamallo C, Perez-Gallego L, Contreras F, Palacios J. beta-catenin expression in pilomatrixomas. Relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles. Br J Dermatol 2001;145(4):576-81.
29. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31(3):306-10.
30. James LF. Teratological research at the USDA-ARS poisonous plant research laboratory. J Nat Toxins 1999;8(1):63-80.
31. Keeler RF. Cyclopamine and related steroidal alkaloid teratogens: Their occurrence, structural relationship, and biologic effects. Lipids 1978;13(10):708-15.
32. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425(6960):846-51.
33. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14(8):994-1004.
34. Rubin JB, Rowitch DH. Medulloblastoma: A problem of developmental biology. Cancer Cell 2002;2(1):7-8.
35. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: Tumours, embryos and stem cells. Nat Rev Cancer 2002;2(5):361-72.
36. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003;422(6929):313-7.
37. Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152(1):43-51.
38. Taylor MD, Zhang X, Liu L, Hui CC, Mainprize TG, Scherer SN, et al. Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene 2004;23(26):4577-83.
39. Grego-Bessa J, Diez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: Another turn of the screw. Cell Cycle 2004;3(6):718-21.
40. Harper JA, Yuan JS, Tan JB, Visan I, Guidos CJ. Notch signaling in development and disease. Clin Genet 2003;64(6):461-72.
41. Maillard I, Pear WS. Notch and cancer: Best to avoid the ups and downs. Cancer Cell 2003;3(3):203-5.
42. Shawber C, Nofziger D, Hsieh JJ, Lindsell C, Bogler O, Hayward D, et al. Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development 1996;122(12):3765-73.
43. Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 1998;9(6):583-9.
44. Borowski C, Martin C, Gounari F, Haughn L, Aifantis I, Grassi F, et al. On the brink of becoming a T cell. Curr Opin Immunol 2002;14(2):200-6.
45. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71.
46. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003;33(2):208-13.
47. Radtke F, Raj K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer 2003;3(10):756-67.
48. Axelson H. The Notch signaling cascade in neuroblastoma: Role of the basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett 2004;204(2):171-8.
49. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64(21):7787-93.
50. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001;61(7):3200-5.
51. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003;33(3):416-21.
52. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol 2003;194(3):356-62.
53. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64(19):6854-7.
54. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004;104(12):3697-704.
55. Labbe JC, Maddox PS, Salmon ED, Goldstein B. PAR proteins regulate microtubule dynamics at the cell cortex in C. elegans. Curr Biol 2003;13(9):707-14.
56. Riechmann V, Gutierrez GJ, Filardo P, Nebreda AR, Ephrussi A. PAR-1 regulates stability of the posterior determinant Oskar by phosphorylation. Nat Cell Biol 2002;4(5):337-42.
57. Wei X, Cheng Y, Luo Y, Shi X, Nelson S, Hyde DR. The zebrafish Pard3 ortholog is required for separation of the eye fields and retinal lamination. Dev Biol 2004;269(1):286-301.
58. Sierko E, Tokajuk P, Zimnoch L, Wojtukiewicz MZ. The location of components of fibrinolytic system in laryngeal cancer]. Pol Merkuriusz Lek 2003;15(85):81-5.
59. Kaufmann R, Junker U, Nuske K, Westermann M, Henklein P, Scheele J, et al. PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 2002;20(1):177-80.
60. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR-1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120(3):303-13.
61. Jin E, Fujiwara M, Pan X, Ghazizadeh M, Arai S, Ohaki Y, et al. Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer 2003;97(3):703-13.
62. Liu Y, Gilcrease MZ, Henderson Y, Yuan XH, Clayman GL, Chen Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. Cancer Lett 2001;169(2):173-80.
63. Booden MA, Eckert LB, Der CJ, Trejo J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 2004;24(5):1990-9.
64. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4(8):909-14.
65. Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease - a preliminary study. Thromb Haemost 1996;76(4):523-8.
66. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003;162(5):1503-13.
67. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003;278(47):46632-42.
68. Zhang X, Hunt JL, Landsittel DP, Muller S, Adler-Storthz K, Ferris RL, et al. Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res 2004;10(24):8451-9.
69. Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: Trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 2004;279(20):20927-34.
70. Shibata K, Yada K, Matsumoto T, Sasaki A, Ohta M, Kitano S. Protease-activating-receptor-2 is frequently expressed in papillary adenocarcinoma of the gallbladder. Oncol Rep 2004;12(5):1013-6.
71. Miyata S, Koshikawa N, Yasumitsu H, Miyazaki K. Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem 2000;275(7):4592-8.
72. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, et al. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 2004;24(6):1401-6.
73. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001;7(5):326-31.
74. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, et al. The role of thrombin in the neovascularization of malignant gliomas: An intrinsic modulator for the up-regulation of vascular endothelial growth factor. Int J Oncol 2002;20(5):921-8.
75. Kaufmann R, Zieger M, Tausch S, Henklein P, Nowak G. Meizothrombin, an intermediate of prothrombin activation, stimulates human glioblastoma cells by interaction with PAR-1-type thrombin receptors. J Neurosci Res 2000;59(5):643-8.
76. Okamoto T, Nishibori M, Sawada K, Iwagaki H, Nakaya N, Jikuhara A, et al. The effects of stimulating protease-activated receptor-1 and -2 in A172 human glioblastoma. J Neural Transm 2001;108(2):125-40.
77. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 2004;30(1):63-9.
78. Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J, et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005;388(Pt 3):967-72.
79. Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 2004;60(2):168-74.
80. Vetterkind S, Boosen M, Scheidtmann KH, Preuss U. Ectopic expression of PAR-4 leads to induction of apoptosis in CNS tumor cell lines. Int J Oncol 2005;26(1):159-67.
81. Galvez-Gastelum FJ, Sandoval-Rodriguez AS, Armendariz-Borunda J. Transforming growth factor-beta as a therapeutic target]. Salud Publica Mex 2004;46(4):341-50.
82. Shepherd TG, Nachtigal MW Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells. Endocrinology 2003;144(8):3306-14.
83. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002;7(12):1191-204.
84. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: Molecular clones and activities. Science 1988;242(4885):1528-34.
85. Oxburgh L, Chu GC, Michael SK, Robertson EJ. TGFbeta superfamily signals are required for morphogenesis of the kidney mesenchyme progenitor population. Development 2004;131(18):4593-605.
86. Hyatt BA, Shangguan X, Shannon JM. FGF-10 induces SP-C and Bmp4 and regulates proximal-distal patterning in embryonic tracheal epithelium. Am J Physiol Lung Cell Mol Physiol 2004;287(6):L1116-26.
87. Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia 2004;18(12):2015-25.
88. Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of Smad proteins with Smad-binding element. J Biol Chem 2002;277(37):33766-75.
89. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004;23(17):3024-32.
90. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, et al. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer 2002;87(6):630-4.
91. Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004;126(1):111-21.
92. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001;28(2):184-7.
93. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, et al. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20(3-4):333-49.
94. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64(3):994-9.
95. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004;64(22):8276-84.
96. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer 2004;4(3):177-83.
97. Furney SJ, Higgins DG, Ouzounis CA, Lopez-Bigas N. Structural and functional properties of genes involved in human cancer. BMC Genomics 2006;7(1):3.
98. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270(5235):467-70.
99. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL. Multiplexed biochemical assays with biological chips. Nature 1993;364(6437):555-6.
100. Mockler TC, Chan S, Sundaresan A, Chen H, Jacobsen SE, Ecker JR. Applications of DNA tiling arrays for whole-genome analysis. Genomics 2005;85(1):1-15.
101. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
102. Arribas J. Matrix metalloproteases and tumor invasion. N Engl J Med 2005;352(19):2020-1r.
103. Paranko J, Pelliniemi LJ, Foidart JM. Epithelio-mesenchymal interface and fibronectin in the differentiation of the rat mesonephric and paramesonephric ducts. Differentiation 1984;27(3):196-204.
104. Griffith CM, Hay ED. Epithelial-mesenchymal transformation during palatal fusion: Carboxyfluorescein traces cells at light and electron microscopic levels. Development 1992;116(4):1087-99.
105. Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, et al. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 2004;166(3):359-67.
106. Ishii M, Merrill AE, Chan YS, Gitelman I, Rice DP, Sucov HM, et al. Msx2 and Twist cooperatively control the development of the neural crest-derived skeletogenic mesenchyme of the murine skull vault. Development 2003;130(24):6131-42.
107. Duband JL, Monier F, Delannet M, Newgreen D. Epithelium-mesenchyme transition during neural crest development. Acta Anat (Basel) 1995;154(1):63-78.
108. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: Normal, pathological, and experimentally induced. Am J Kidney Dis 1995;26(4):678-90.
109. Sorokin L, Sonnenberg A, Aumailley M, Timpl R, Ekblom P. Recognition of the laminin E8 cell-binding site by an integrin possessing the alpha 6 subunit is essential for epithelial polarization in developing kidney tubules. J Cell Biol 1990;111(3):1265-73.
110. Wilson L, Maden M. The mechanisms of dorsoventral patterning in the vertebrate neural tube. Dev Biol 2005;282(1):1-13.
111. Dyer MA, Farrington SM, Mohn D, Munday JR, Baron MH. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development 2001;128(10):1717-30.
112. Black GC, Mazerolle CJ, Wang Y, Campsall KD, Petrin D, Leonard BC, et al. Abnormalities of the vitreoretinal interface caused by dysregulated Hedgehog signaling during retinal development. Hum Mol Genet 2003;12(24):3269-76.